Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma

Thorax

Volumn 63, Issue 12, 2008, Pages 1070-1075

  Hothersall, E J ^a   Chaudhuri, R ^a   McSharry, C ^a   Donnelly, I ^a   Lafferty, J ^a   McMahon, A D ^a   Weir, C J ^a   Meiklejohn, J ^a   Sattar, N ^a   McInnes, I ^a   Wood, S ^a   Thomson, N C ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CORTICOSTEROID; PLACEBO;

ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPUTUM CYTODIAGNOSIS;

EID: 57149101949     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2008.100198     Document Type: Article

References (41)

1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Group. N Engl J Med 1995;333:1301-7.
2. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003;170:1524-30.
3. McKay A, Leung BP, McInnes IB, et al. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004;172:2903-8.
4. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-70.
5. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61:729-34.
6. Nath N, Giri S, Prasad R, et al. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004;172:1273-86.
7. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
8. Kay AB. Allergy and allergic diseases: first of two parts. N Engl J Med 2001;344:30-7.
9. Yeh YF, Huang SL. Enhancing effect of dietary cholesterol and inhibitory effect of pravastatin on allergic pulmonary inflammation. J Biomed Sci 2004;11:599-606.
10. Kim DY, Ryu SY, Lim JE, et al. Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model. Eur J Pharmacol 2007;557:76-86.
11. Menzies D, Nair A, Meldrum KT, et al. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol 2007;119:328-35.
12. Joukhadar C, Klein N, Prinz M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with nypercholesterolaemia. Thromb Haemost 2001;85:47-51.
13. Chan KY, Boucher ES, Gandhi PJ, et al. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health-Syst Pharm 2004;61:1676-81.
14. Santanello N, Barber B, Reiss T, et al. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997;10:646-51.
15. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-34.
16. Juniper E, O'Byrne P, Guyatt G, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7.
17. Cockcroft D, Killian D, Mellon J, et al. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977;7:235-43.
18. Crapo R, Casaburi R, Coates A, et al. Guidelines for methacholine and exercise challenge testing - 1999 Am J Respir Crit Care Med 2000;161:309-29.
19. Pavord ID, Pizzichini MMM, Pizzichini E, et al. The use of induced sputum to investigate airway inflammation. Thorax 1997;52:498-501.
20. ATS/ERS. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912- 30.
21. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
22. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-9.
23. Laufs U, Wassmann S, Hilgers S, et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001;88:1306-7.
24. van de Garde EMW, Hak E, Souverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;61:957-61.
25. Takeda N, Kondo M, Ito S, et al. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol 2006;35:722-9.
26. Lai W-T, Lee K-T, Chu C-S, et al. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation. Int J Cardiol 2005;98:459-64.
27. Amarenco P, Labreucne J, Lavallee P, et al. Stalins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004;35:2902-9.
28. Abe N, Osanai T, Fujiwara T, et al. C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. Life Sci 2006;78:1021-8.
29. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
30. Sakai M, Kobori S, Matsumura T, et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997;133:51-9.
31. . Kostikas K, Gaga M, Papatheodorou G, et al. Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest 2005;127:1553-9.
32. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007;357:1841-54.
33. Veillard NR, Braunersreuther V, Arnaud C, et al. Simvastatin modulates chernokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006;188:51-8.
34. Pozo M, de Nicolas R, Egido J, et al. Simvastatin inhibits the migration and adhesion of monocytic cells and disorganizes the cytoskeleton of activated endothelial cells. Eur J Pharmacol 2006;548:53-63.
35. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes. Inflamm Res 2002;51:58-62.
36. Xu Z-M, Zhao S-p, Li Q-Z, et al. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 2003;338:17-24.
37. Kowalski J, Okopien B, Madej A, et al. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia. Eur J Clin Pharmacol 2003;59:189-93.
38. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-88.
39. Morimoto K, Janssen WJ, Fessier MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006;176:7657-65.
40. Lee J-H, Lee D-S, Kim E-K, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005;172:987-93.
41. Fessier MB, Young SK, Jeyaseelan S, et al. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Atherosclerosis 2005;171:51-8.